HKEX: 9939
Interim report 2026
Earlier from Kintor Pharmaceutical
- Phase II Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult Aga In China Reached Primary Endpoint
- Kintor Pharmaceutical: Pharma Announces Publication of Phase Ib/II Data from GT90001 and Nivolumab Combination Therapy for Advanced HCC in BMC Medicine
- Kintor Pharmaceutical: Pharma Announces the Approval of Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China
- Kintor Pharmaceutical: Pharma Announces 2023 Interim Results and Recent Business Highlights